HSPG2 and pancreatic neoplasm: In pancreatic cancer, tumor cells epigenetically reprogram CAFs that promote HSPG2 release through an NF-κB-dependent pathway, increasing invasion, metastasis, and chemoresistance to gemcitabine [39].